George Church to Join Endpoints 11 Awards on September 18

Prominent geneticist George Church will participate in a fireside chat during the upcoming Endpoints 11 awards dinner on September 18 in Boston. Church, known for co-founding approximately 50 biotech companies, will share insights on the evolving landscape of biotechnology, particularly in areas like cell and gene therapy. His work often ventures into ambitious territories, such as longevity and the revival of extinct species, attracting a unique group of adventurous investors.

Church’s contributions to the field have inspired numerous scientists who have emerged from his lab with their own innovative plans. His vision often challenges conventional boundaries, making him a significant figure among the most groundbreaking minds in biotechnology. The Endpoints 11 awards recognize the most exciting private biotechs in drug development, showcasing the industry’s potential and future directions.

Celebrating Innovation in Biotech

The Endpoints team, led by executive editor Drew Armstrong, is currently finalizing the list of nominated startups that will be highlighted during the gala. The team has been working diligently, with a deadline set for late August to complete candidate profiles. This year’s event promises a unique opportunity for attendees to engage with leading figures in the biotech world and reflect on the future of the industry.

Attendees at the awards dinner will not only have the chance to celebrate the achievements of those pushing the boundaries of science but also to network with other professionals in the field. Early bird tickets are available for a limited time, allowing participants to secure their place at this anticipated event.

The Endpoints 11 awards serve as a platform to explore the frontiers of science and the origins of the next generation of biotechs. With Church’s participation, the evening is set to be an enlightening experience for all involved, emphasizing the importance of innovation in the biopharmaceutical sector.

This gathering will not only recognize current achievements but also highlight the advancements that lie ahead, ensuring that the dialogue around biotechnology remains vibrant and forward-thinking.